328 related articles for article (PubMed ID: 9356498)
1. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.
Levitskaya J; Sharipo A; Leonchiks A; Ciechanover A; Masucci MG
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12616-21. PubMed ID: 9356498
[TBL] [Abstract][Full Text] [Related]
2. Avoiding proteasomal processing: the case of EBNA1.
Dantuma NP; Sharipo A; Masucci MG
Curr Top Microbiol Immunol; 2002; 269():23-36. PubMed ID: 12224511
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.
Levitskaya J; Coram M; Levitsky V; Imreh S; Steigerwald-Mullen PM; Klein G; Kurilla MG; Masucci MG
Nature; 1995 Jun; 375(6533):685-8. PubMed ID: 7540727
[TBL] [Abstract][Full Text] [Related]
4. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition.
Tellam J; Sherritt M; Thomson S; Tellam R; Moss DJ; Burrows SR; Wiertz E; Khanna R
J Biol Chem; 2001 Sep; 276(36):33353-60. PubMed ID: 11435434
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal.
Dantuma NP; Heessen S; Lindsten K; Jellne M; Masucci MG
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8381-5. PubMed ID: 10890896
[TBL] [Abstract][Full Text] [Related]
6. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.
Yin Y; Manoury B; Fåhraeus R
Science; 2003 Sep; 301(5638):1371-4. PubMed ID: 12958359
[TBL] [Abstract][Full Text] [Related]
7. Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing.
Zhang M; Coffino P
J Biol Chem; 2004 Mar; 279(10):8635-41. PubMed ID: 14688254
[TBL] [Abstract][Full Text] [Related]
8. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
9. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
[TBL] [Abstract][Full Text] [Related]
10. cis-Inhibition of proteasomal degradation by viral repeats: impact of length and amino acid composition.
Sharipo A; Imreh M; Leonchiks A; Brändén C; Masucci MG
FEBS Lett; 2001 Jun; 499(1-2):137-42. PubMed ID: 11418128
[TBL] [Abstract][Full Text] [Related]
11. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.
Tellam J; Connolly G; Green KJ; Miles JJ; Moss DJ; Burrows SR; Khanna R
J Exp Med; 2004 May; 199(10):1421-31. PubMed ID: 15148340
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitor induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5.
Pokrovskaja K; Mattsson K; Kashuba E; Klein G; Szekely L
J Gen Virol; 2001 Feb; 82(Pt 2):345-358. PubMed ID: 11161273
[TBL] [Abstract][Full Text] [Related]
13. The ubiquitin/proteasome system in Epstein-Barr virus latency and associated malignancies.
Dantuma NP; Masucci MG
Semin Cancer Biol; 2003 Feb; 13(1):69-76. PubMed ID: 12507558
[TBL] [Abstract][Full Text] [Related]
14. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
Khanna R; Burrows SR; Steigerwald-Mullen PM; Moss DJ; Kurilla MG; Cooper L
Int Immunol; 1997 Oct; 9(10):1537-43. PubMed ID: 9352359
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
Gavioli R; Vertuani S; Masucci MG
Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
[TBL] [Abstract][Full Text] [Related]
16. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
Lee SP; Brooks JM; Al-Jarrah H; Thomas WA; Haigh TA; Taylor GS; Humme S; Schepers A; Hammerschmidt W; Yates JL; Rickinson AB; Blake NW
J Exp Med; 2004 May; 199(10):1409-20. PubMed ID: 15148339
[TBL] [Abstract][Full Text] [Related]
17. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
[TBL] [Abstract][Full Text] [Related]
18. Degradation of the epstein-barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue.
Aviel S; Winberg G; Massucci M; Ciechanover A
J Biol Chem; 2000 Aug; 275(31):23491-9. PubMed ID: 10807912
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus activates beta-catenin in type III latently infected B lymphocyte lines: association with deubiquitinating enzymes.
Shackelford J; Maier C; Pagano JS
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15572-6. PubMed ID: 14663138
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.
Blake NW; Moghaddam A; Rao P; Kaur A; Glickman R; Cho YG; Marchini A; Haigh T; Johnson RP; Rickinson AB; Wang F
J Virol; 1999 Sep; 73(9):7381-9. PubMed ID: 10438828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
